These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33482697)

  • 81. Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.
    Oliveira-Ferrer L; Wellbrock J; Bartsch U; Penas EM; Hauschild J; Klokow M; Bokemeyer C; Fiedler W; Schuch G
    Mol Cancer; 2013 Nov; 12(1):144. PubMed ID: 24257371
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization.
    Shao R; Taylor SL; Oh DS; Schwartz LM
    Oncotarget; 2015 Dec; 6(38):40507-18. PubMed ID: 26439689
    [TBL] [Abstract][Full Text] [Related]  

  • 84. In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued.
    van Lith SA; Roodink I; Verhoeff JJ; Mäkinen PI; Lappalainen JP; Ylä-Herttuala S; Raats J; van Wijk E; Roepman R; Letteboer SJ; Verrijp K; Leenders WP
    Oncotarget; 2016 Nov; 7(44):71594-71607. PubMed ID: 27689404
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
    Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
    Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
    [TBL] [Abstract][Full Text] [Related]  

  • 86. VEGF Manipulation in Glioblastoma.
    Weathers SP; de Groot J
    Oncology (Williston Park); 2015 Oct; 29(10):720-7. PubMed ID: 26470893
    [TBL] [Abstract][Full Text] [Related]  

  • 87. VEGF as a potential target in lung cancer.
    Frezzetti D; Gallo M; Maiello MR; D'Alessio A; Esposito C; Chicchinelli N; Normanno N; De Luca A
    Expert Opin Ther Targets; 2017 Oct; 21(10):959-966. PubMed ID: 28831824
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
    Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
    J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
    Wong ET; Brem S
    J Natl Compr Canc Netw; 2008 May; 6(5):515-22. PubMed ID: 18492463
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models.
    Park JH; Kim MJ; Kim WJ; Kwon KD; Ha KT; Choi BT; Lee SY; Shin HK
    Cancer Lett; 2020 May; 478():71-81. PubMed ID: 32173479
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass.
    Sousa F; Costa-Pereira AI; Cruz A; Ferreira FJ; Gouveia M; Bessa J; Sarmento B; Travasso RDM; Mendes Pinto I
    J Control Release; 2021 Nov; 339():381-390. PubMed ID: 34592385
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Update on bevacizumab and other angiogenesis inhibitors for brain cancer.
    Rinne ML; Lee EQ; Nayak L; Norden AD; Beroukhim R; Wen PY; Reardon DA
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):137-53. PubMed ID: 23668489
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies.
    Boer JC; Walenkamp AM; den Dunnen WF
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):38-48. PubMed ID: 24933160
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dianhydrogalactitol, a potential multitarget agent, inhibits glioblastoma migration, invasion, and angiogenesis.
    Jiang X; Huang Y; Wang X; Liang Q; Li Y; Li F; Fu X; Huang C; Liu H
    Biomed Pharmacother; 2017 Jul; 91():1065-1074. PubMed ID: 28525947
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 100. Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition.
    Krishnan S; Szabo E; Burghardt I; Frei K; Tabatabai G; Weller M
    Oncotarget; 2015 Sep; 6(26):22480-95. PubMed ID: 26090865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.